A2AR/MGLUR5 ANTAGONIST COMBINATION ANTIPARKINSONIAN THERAPY IN MPTP MONKEYS
A2AR/MGLUR5 拮抗剂联合抗帕金森病治疗 MPTP 猴
基本信息
- 批准号:8357543
- 负责人:
- 金额:$ 3.29万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-08-01 至 2012-04-30
- 项目状态:已结题
- 来源:
- 关键词:Adenosine A2A ReceptorAdverse effectsAffinityAntiparkinson AgentsBasal GangliaBehaviorBehavioralBiological AvailabilityCell NucleusDopamineDrug ReceptorsFundingGRM5 geneGoldGrantKW-6002MeasuresModelingMonitorMonkeysMotorNational Center for Research ResourcesNatureNeurotransmittersParkinson DiseaseParkinsonian DisordersPharmaceutical PreparationsPharmacological TreatmentPrimatesPrincipal InvestigatorPublishingResearchResearch InfrastructureResourcesSourceSystemTestingTimeUnited States National Institutes of Healthcostmetabotropic glutamate receptor 5receptor
项目摘要
This subproject is one of many research subprojects utilizing the resources
provided by a Center grant funded by NIH/NCRR. Primary support for the subproject
and the subproject's principal investigator may have been provided by other sources,
including other NIH sources. The Total Cost listed for the subproject likely
represents the estimated amount of Center infrastructure utilized by the subproject,
not direct funding provided by the NCRR grant to the subproject or subproject staff.
Current pharmacological treatments for Parkinson's Disease (PD) act on the dopamine neurotransmitter system and cause debilitating motor side effects. This project seeks to study new potential antiparkinsonian drugs (and their mechanisms of action) that act on other neurotransmitter systems and are therefore not likely to cause motor side effects. Antagonists of metabotropic glutamate receptor 5 (mGluR5) and adenosine A2A receptor (A2AR) are the focus of this study. These drugs will be injected systemically or locally into various nuclei of the basal ganglia of MPTP-treated parkinsonian monkeys (the gold-standard model of PD), and their motor behavior will be monitored. These drugs will be administered both alone and together.
We have found that when injected systemically, the mGluR5 antagonist MTEP provides a modest anti-akinetic benefit to MPTP-treated monkeys. After trying several different A2AR antagonists, we have been unable to measure any behavioral antiparkinsonian effect in our monkeys, whether the drugs were administered systemically or locally in the basal ganglia, either given alone or in combination with mGluR5 antagonist. We were unable to obtain the only A2AR drug published to have antiparkinsonian effects in monkeys at the time (KW-6002), due to the proprietary nature of the drug. Since then, one more A2AR drug (preladenant) has been published to have antiparkinsonian effects in monkeys. We have made arrangements to get some of this new compound, with better affinity/selectivity/bioavailability, for testing in our monkeys.
这个子项目是利用资源的许多研究子项目之一。
由NIH/NCRR资助的中心拨款提供。对子项目的主要支持
子项目的首席调查员可能是由其他来源提供的,
包括美国国立卫生研究院的其他来源。为子项目列出的总成本可能
表示该子项目使用的中心基础设施的估计数量,
不是由NCRR赠款提供给次级项目或次级项目工作人员的直接资金。
目前帕金森氏病(PD)的药物治疗作用于多巴胺神经递质系统,并引起衰弱的运动副作用。该项目旨在研究新的潜在的抗帕金森病药物(及其作用机制),这些药物作用于其他神经递质系统,因此不太可能引起运动副作用。代谢性谷氨酸受体5(MGluR5)和腺苷A2a受体(A2AR)的拮抗剂是本研究的重点。这些药物将被系统或局部注射到MPTP治疗的帕金森病猴子的基底节的不同核中(帕金森病的金标准模型),并将监测它们的运动行为。这些药物将单独和一起使用。
我们发现,当系统注射mGluR5拮抗剂MTEP时,对MPTP治疗的猴子提供了适度的抗运动障碍益处。在尝试了几种不同的A2AR拮抗剂后,无论这些药物是系统地还是在基底节局部给药,无论是单独给药还是与mGluR5拮抗剂联合给药,我们都无法在猴子身上测量到任何行为上的抗帕金森效应。由于A2AR药物的专利性质,我们当时无法获得唯一在猴子中具有抗帕金森病作用的A2AR药物(KW-6002)。从那时起,又有一种A2AR药物(早产素)被公布在猴子身上具有抗帕金森症的作用。我们已经做出安排,让一些新化合物具有更好的亲和力/选择性/生物利用度,用于在我们的猴子身上进行测试。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Yoland Smith其他文献
Yoland Smith的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Yoland Smith', 18)}}的其他基金
Connectome of Motor Corticofugal Neurons in Parkinsonian Monkeys
帕金森猴运动皮质神经元的连接组
- 批准号:
10284849 - 财政年份:2021
- 资助金额:
$ 3.29万 - 项目类别:
Connectome of Motor Corticofugal Neurons in Parkinsonian Monkeys
帕金森猴运动皮质神经元的连接组
- 批准号:
10495224 - 财政年份:2021
- 资助金额:
$ 3.29万 - 项目类别:
Pathophysiology of the Pedunculopontine Nucleus in Parkinson's Disease
帕金森病桥脚核的病理生理学
- 批准号:
10213844 - 财政年份:2017
- 资助金额:
$ 3.29万 - 项目类别:
Pathophysiology of the Pedunculopontine Nucleus in Parkinson's Disease
帕金森病桥脚核的病理生理学
- 批准号:
9975917 - 财政年份:2017
- 资助金额:
$ 3.29万 - 项目类别:
Pathophysiology of the Pedunculopontine Nucleus in Parkinson's Disease
帕金森病桥脚核的病理生理学
- 批准号:
9404759 - 财政年份:2017
- 资助金额:
$ 3.29万 - 项目类别:
ANATOMICAL AND PHYSIOLOGICAL CHARACTERIZATION OF THE THALAMOSTRIATAL SYSTEM
丘纹系统的解剖学和生理学特征
- 批准号:
8357545 - 财政年份:2011
- 资助金额:
$ 3.29万 - 项目类别:
EVALUATION OF PROSAVIN EFFICACY TO MPTP-LESIONED MACAQUES
PROSAVIN 对 MPTP 损伤的猕猴的功效评估
- 批准号:
8357571 - 财政年份:2011
- 资助金额:
$ 3.29万 - 项目类别:
相似海外基金
Unraveling Adverse Effects of Checkpoint Inhibitors Using iPSC-derived Cardiac Organoids
使用 iPSC 衍生的心脏类器官揭示检查点抑制剂的副作用
- 批准号:
10591918 - 财政年份:2023
- 资助金额:
$ 3.29万 - 项目类别:
Optimization of mRNA-LNP vaccine for attenuating adverse effects and analysis of mechanism behind adverse effects
mRNA-LNP疫苗减轻不良反应的优化及不良反应机制分析
- 批准号:
23K15383 - 财政年份:2023
- 资助金额:
$ 3.29万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of adverse effects of combined exposure to low-dose chemicals in the living environment on allergic diseases and attempts to reduce allergy
阐明生活环境中低剂量化学品联合暴露对过敏性疾病的不良影响并尝试减少过敏
- 批准号:
23H03556 - 财政年份:2023
- 资助金额:
$ 3.29万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Green tea-based nano-enhancer as an adjuvant for amplified efficacy and reduced adverse effects in anti-angiogenic drug treatments
基于绿茶的纳米增强剂作为抗血管生成药物治疗中增强疗效并减少不良反应的佐剂
- 批准号:
23K17212 - 财政年份:2023
- 资助金额:
$ 3.29万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Effects of Tobacco Heating System on the male reproductive function and towards to the reduce of the adverse effects.
烟草加热系统对男性生殖功能的影响以及减少不利影响。
- 批准号:
22H03519 - 财政年份:2022
- 资助金额:
$ 3.29万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Mitigating the Adverse Effects of Ultrafines in Pressure Filtration of Oil Sands Tailings
减轻油砂尾矿压力过滤中超细粉的不利影响
- 批准号:
563657-2021 - 财政年份:2022
- 资助金额:
$ 3.29万 - 项目类别:
Alliance Grants
1/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
1/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10521849 - 财政年份:2022
- 资助金额:
$ 3.29万 - 项目类别:
4/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
4/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10671022 - 财政年份:2022
- 资助金额:
$ 3.29万 - 项目类别:
2/4 Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
2/4 ECT 结果和不良反应的破译机制(DECODE)
- 批准号:
10670918 - 财政年份:2022
- 资助金额:
$ 3.29万 - 项目类别:
Adverse Effects of Using Laser Diagnostics in High-Speed Compressible Flows
在高速可压缩流中使用激光诊断的不利影响
- 批准号:
RGPIN-2018-04753 - 财政年份:2022
- 资助金额:
$ 3.29万 - 项目类别:
Discovery Grants Program - Individual